OptimizeRx CEO William Febbo to step down Dec 31; President Stephen Silvestro named interim CEO

OptimizeRx Corp

CEO William Febbo departs effective Dec 31, 2024; will provide advisory services through March 2025.
Board appoints President Stephen Silvestro as interim CEO; search for permanent CEO initiated.
Company reaffirms FY2024 guidance; expects revenue and adjusted EBITDA at higher end of range.
Febbo had been CEO for nearly nine years; board expresses gratitude and confidence in team.
Silvestro joined OptimizeRx in 2019, became President in October 2023; previously Chief Commercial Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.